课题基金 / 基金详情

Integrated Precision Medicine Technology and Approach for Optimal Drug Therapy for Canadians

Integrated Precision Medicine Technology and Approach for Optimal Drug Therapy for Canadians
为加拿大人提供最佳药物治疗的综合精准医疗技术和方法
批准号：
441756
负责人：
Kim Richard B
金额：
$145.34万
依托单位：
London Health Sciences Centre Res. Inc. (Ont.)
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2020
资助国家：
加拿大
项目状态：
已结题
起止时间：
2020-12-01 至 2024-12-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=441756&lang=en
关键词：
Clinical Pharmacology Drug Interactions Drug Metabolism Pharmacogenetics Pharmacogenomics

项目摘要

项目成果

Kim Richard B的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Patients who are diagnosed with cancer face a daunting journey that starts with anxiety and uncertainty associated with the diagnosis as well as having to deal with important but sometime painful and grueling treatments including surgery, chemotherapy, an
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Organic Anion Transporting Polypeptide (OATP), P-glycoprotein (P-gp), and Breast Cancer Resistance Protein (BCRP) transporters modulate tamoxifen response during breast cancer therapy
  • 批准号：
    452037
  • 项目类别：
    Operating Grants
  • 资助金额：
    $47.93万
  • 财政年份：
    2021
  • 负责人：
    Kim Richard B
  • 依托单位：
    University of Western Ontario
Clinical and pharmacogenomic predictors of inter-patient variation in direct acting oral anticoagulant (DOAC) plasma concentrations in real-world patients
  • 批准号：
    338124
  • 项目类别：
    Miscellaneous Programs
  • 资助金额：
    $36.24万
  • 财政年份：
    2015
  • 负责人：
    Kim Richard B
  • 依托单位：
    University of Western Ontario
Best Brains Exchange: ''Canada as a Leader in the Development and Deployment of Precision/Personalized Medicine'' March 23, 2015 in Ottawa, ON.
DSEN Pharmacogenomics of Adverse Reaction Events National Team (DSEN-PREVENT)
海外基金